Biologic markers determine both the risk and the timing of recurrence in breast cancer

Breast Cancer Research and Treatment

Volumn 129, Issue 2, 2011, Pages 607-616

  Esserman, Laura J ^a   Moore, Dan H ^b   Tsing, Pamela J ^a   Chu, Philip W ^a   Yau, Christina ^c   Ozanne, Elissa ^d   Chung, Robert E ^e   Tandon, Vickram J ^a   Park, John W ^b   Baehner, Frederick L ^b   Kreps, Stig ^a   Tutt, Andrew N J ^f   Gillett, Cheryl E ^g   Benz, Christopher C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Gene signatures; Hormone therapy; Recurrence; Risk; Risk partitioning

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LONDON; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80052641331     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1564-5     Document Type: Article

References (39)

1. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D Sep 11 (Pubitemid 32878711)
2. LJ van't Veer H Dai MJ van de Vijver, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 530 536 10.1038/415530a Jan 31 (Pubitemid 34130608)
3. Z Hu C Fan DS Oh, et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 96 16643655 10.1186/1471-2164-7-96 (Pubitemid 43786485)
4. JS Ross C Hatzis WF Symmans L Pusztai GN Hortobagyi 2008 Commercialized multigene predictors of clinical outcome for breast cancer Oncologist 13 5 477 493 18515733 10.1634/theoncologist.2007-0248 (Pubitemid 351872866)
5. L Pusztai 2009 Gene expression profiling of breast cancer Breast Cancer Res 11 Suppl 3 S11 20030862 10.1186/bcr2430
6. A Tutt A Wang C Rowland, et al. 2008 Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature BMC Cancer 8 339 19025599 10.1186/1471-2407-8-339
7. Y Wang JG Klijn Y Zhang, et al. 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 9460 671 679 15721472 1:CAS:528:DC%2BD2MXhsVOitLk%3D Feb 19-25 (Pubitemid 40260888)
8. HY Chang DS Nuyten JB Sneddon, et al. 2005 Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci USA 102 10 3738 3743 15701700 10.1073/pnas.0409462102 1:CAS:528:DC%2BD2MXisVOgtr4%3D Mar 8 (Pubitemid 40354681)
9. S Paik S Shak G Tang, et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2817 2826 15591335 10.1056/NEJMoa041588 1:CAS:528:DC%2BD2MXhslymsw%3D%3D Dec 30 (Pubitemid 40051905)
10. LD Miller J Smeds J George, et al. 2005 An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival Proc Natl Acad Sci USA 102 38 13550 13555 16141321 10.1073/pnas.0506230102 1:CAS:528:DC%2BD2MXhtVygtr7I Sep 20 (Pubitemid 41420886)
11. C Sotiriou P Wirapati S Loi, et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 4 262 272 16478745 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D Feb 15 (Pubitemid 43264710)
12. P Wirapati C Sotiriou S Kunkel, et al. 2008 Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures Breast Cancer Res 10 4 R65 18662380 10.1186/bcr2124
13. C Desmedt B Haibe-Kains P Wirapati, et al. 2008 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes Clin Cancer Res 14 16 5158 5165 18698033 10.1158/1078-0432.CCR-07-4756 1:CAS:528:DC%2BD1cXpslKgur4%3D Aug 15
14. EA Lobb PN Butow DT Kenny MH Tattersall 1999 Communicating prognosis in early breast cancer: do women understand the language used? Med J Aust 171 6 290 294 10560442 1:STN:280:DC%2BD3c%2FisVagsA%3D%3D Sep 20 (Pubitemid 29445719)
15. EA Lobb DT Kenny PN Butow MH Tattersall 2001 Women's preferences for discussion of prognosis in early breast cancer Health Expect 4 1 48 57 11286599 10.1046/j.1369-6513.2001.00119.x 1:STN:280:DC%2BD3MvnvFKgtA%3D%3D (Pubitemid 32230117)
16. MF Pichon P Broet H Magdelenat, et al. 1996 Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers Br J Cancer 73 12 1545 1551 8664127 10.1038/bjc.1996.291 1:STN:280:DyaK283mt1Wgug%3D%3D (Pubitemid 26235381)
17. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 5 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
18. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 5 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
19. Atkinson EJ, Therneau TM (2000) An introduction to recursive partitioning using the RPART routines
20. Breiman L, Friedman J, Olshen R, Stone C (1984) Classification and regression trees. Wadsworth International Group, Belmont, CA
21. AJ Minn GP Gupta PM Siegel, et al. 2005 Genes that mediate breast cancer metastasis to lung Nature 436 7050 518 524 16049480 10.1038/nature03799 1:CAS:528:DC%2BD2MXmsFCgs7o%3D Jul 28 (Pubitemid 41112921)
22. C Desmedt F Piette S Loi, et al. 2007 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clin Cancer Res 13 11 3207 3214 17545524 10.1158/1078-0432.CCR-06-2765 1:CAS:528:DC%2BD2sXmtVajur0%3D Jun 1 (Pubitemid 46944903)
23. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D Aug 17
24. AE Teschendorff C Caldas 2008 A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer Breast Cancer Res 10 4 R73 18755024 10.1186/bcr2138
25. C Yau L Esserman DH Moore F Waldman J Sninsky CC Benz 2010 A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer Breast Cancer Res 12 5 R85 20946665 10.1186/bcr2753 Oct 14
26. F Reyal MH van Vliet NJ Armstrong, et al. 2008 A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer Breast Cancer Res 10 6 R93 19014521 10.1186/bcr2192
27. M Pintilie 2007 Analysing and interpreting competing risk data Stat Med 26 6 1360 1367 16900575 10.1002/sim.2655 Mar 15 (Pubitemid 46380846)
28. MC Cheang D Voduc C Bajdik, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 5 1368 1376 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D Mar 1 (Pubitemid 351413917)
29. A Prat JS Parker O Karginova, et al. 2010 Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res 12 5 R68 20813035 10.1186/bcr2635 Sep 2
30. TJ Hobday EA Perez 2005 Molecularly targeted therapies for breast cancer Cancer Control 12 2 73 81 15855890 (Pubitemid 40647050)
31. J O'Shaughnessy C Osborne JE Pippen, et al. 2011 Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 3 205 214 21208101 10.1056/NEJMoa1011418 Jan 20
32. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 10 2738 2746 8874335 1:STN:280:DyaK2s%2FivVehsw%3D%3D (Pubitemid 26329660)
33. EBCTCG 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 May 14-20 (Pubitemid 40719106)
34. PE Goss 2007 Letrozole in the extended adjuvant setting: MA.17 Breast Cancer Res Treat 105 Suppl 1 45 53 17912635 10.1007/s10549-007-9698-1 1:CAS:528:DC%2BD2sXhtlektrfM (Pubitemid 47524799)
35. PE Goss JN Ingle S Martino, et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 19 1793 1802 14551341 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D Nov 6 (Pubitemid 37362955)
36. AC Wolff ME Hammond JN Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 1 18 43 19548375 1:CAS:528:DC%2BD2sXhsVOmu74%3D (Pubitemid 46174133)
37. M Buyse S Loi L van't Veer, et al. 2006 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 17 1183 1192 16954471 10.1093/jnci/djj329 1:CAS:528:DC%2BD28Xps1yjtLw%3D Sep 6 (Pubitemid 44390989)
38. IA Olivotto CD Bajdik PM Ravdin, et al. 2005 Population-based validation of the prognostic model ADJUVANT! for early breast cancer J Clin Oncol 23 12 2716 2725 15837986 10.1200/JCO.2005.06.178 Apr 20 (Pubitemid 46179461)
39. A Mrozkowiak WP Olszewski A Piascik WT Olszewski 2004 HER2 status in breast cancer determined by IHC and FISH: comparison of the results Pol J Pathol 55 4 165 171 15757204 1:CAS:528:DC%2BD2MXivVOnur0%3D (Pubitemid 40321625)